Cerebral Infarction

Pipeline Programs

Companies

Clinical Trials

1 recruiting

Approved Products

Pipeline by Development Stage

Preclinical

Phase 1

Phase 1/2

Phase 2

Phase 2/3

Phase 3

On Market

Early DiscoveryClinical DevelopmentMarket

On Market (1)

Approved therapies currently available

PLAVIXApproved

clopidogrel

Sanofi

oral1997

7M Part D

Competitive Landscape

10 companies ranked by most advanced pipeline stage

Pre

P1/2

P2/3

Mkt

OtsukaJapan - Tokushima

9 programs

AspirinPhase 41 trial

CilostazolPhase 41 trial

+4 more programs

Active Trials

NCT00216749Completed650Est. Oct 2007

NCT00202020Completed720Est. Jan 2006

NCT00766545Completed1,095Est. Mar 1997

+6 more trials

SanofiPARIS, France

1 program

PLAVIX(clopidogrel)PHASE_45 trials

Active Trials

NCT00862420Completed431Est. May 2011

NCT00386191Completed1,110Est. Dec 2008

NCT00300339Completed599Est. Dec 2007

+2 more trials

BiocorpFrance - Issoire

1 program

kallikreinPhase 41 trial

Active Trials

NCT02562183Unknown2,186Est. Nov 2018

Techpool BiopharmaChina - Guangzhou

1 program

kallikreinPhase 4

Sharp TherapeuticsPA - Pittsburgh

1 program

Vorapaxar 2.5 mgPhase 2

MSDIreland - Ballydine

1 program

Vorapaxar 2.5 mgPhase 21 trial

Active Trials

NCT00684515Completed90Est. Nov 2007

UNION therapeuticsDenmark - Hellerup

1 program

A Multi-center Prospective Study of Branch Atheromatous Disease in ChinaN/A1 trial

Active Trials

NCT04973774Unknown600Est. Jun 2025

Gedeon RichterHungary - Budapest

1 program

Chinese Assessment for Vinpocetine In NeurologyN/A1 trial

Active Trials

NCT01400035Completed610Est. May 2013

Dong-A STKorea - Seoul

1 program

Dipeptidyl peptidase-4 inhibitorN/A1 trial

Active Trials

NCT05817097Unknown22,119Est. Dec 2024

Merck & Co.RAHWAY, NJ

1 program

Vorapaxar 2.5 mgPHASE_2

Trial Timeline

Clinical trial activity over time

2021

2022

2023

2024

2025

2026

2027

2028

OtsukaAspirin

Biocorpkallikrein

OtsukaCilostazol

OtsukaAspirin

Sanoficlopidogrel

OtsukaCilostazol

Otsukaclopidogrel

OtsukaCilostazol

Sanoficlopidogrel

OtsukaCilostazol 200mg/day Oral

Sanoficlopidogrel

Otsukacilostazol

MSDVorapaxar 2.5 mg

Sanoficlopidogrel

Showing 15 of 19 trials with date data

Clinical Trials (19)

Total enrollment: 53,125 patients across 19 trials

NCT06757764 OtsukaAspirin

The Effect and Safety of Combined Anti-platelet Treatment in Acute Ischemic Stroke Due to Large Artery Atherosclerosis

Start: Jul 2025Est. completion: Mar 20282,340 patients

Phase 4Recruiting

NCT02562183 Biocorpkallikrein

The Study to Reevaluate the Safety and Efficacy of Human Urinary Kallikrein

Start: Aug 2015Est. completion: Nov 20182,186 patients

Phase 4Unknown

NCT00446641 OtsukaCilostazol

Overcome Biochemical Aspirin Resistance Through Cilostazol Combination

Start: Mar 2007Est. completion: Jul 2008244 patients

Phase 4Completed

NCT00741286 OtsukaAspirin

Effect of Cilostazol in the Acute Lacunar Infarction Based on Pulsatility Index of Transcranial Doppler

Start: Nov 2006Est. completion: Oct 2008203 patients

Phase 4Completed

NCT00386191 Sanoficlopidogrel

Safety and Efficacy of Clopidogrel for Cerebral Infarction Treatment

Start: Sep 2006Est. completion: Dec 20081,110 patients

Phase 4Completed

NCT00272454 OtsukaCilostazol

Cilostazol in Acute Ischemic Stroke Treatment (CAIST)

Start: Jan 2006Est. completion: Sep 2008468 patients

Phase 4Completed

NCT00130039 Otsukaclopidogrel

Trial of Cilostazol in Symptomatic Intracranial Arterial Stenosis II

Start: Aug 2005Est. completion: Jan 2009457 patients

Phase 4Completed

NCT00234065 OtsukaCilostazol

Post-marketing Study of Cilostazol (Cilostazol Stroke Prevention Study 2)

Start: Dec 2003Est. completion: Dec 20082,800 patients

Phase 4Completed

NCT00862420 Sanoficlopidogrel

Safety Evaluation of Clopidogrel Sulfate in Patients With Peripheral Arterial Disease

Start: Feb 2009Est. completion: May 2011431 patients

Phase 3Completed

NCT00325390 Sanoficlopidogrel

Efficacy and Safety in Patients With Acute Coronary Syndrome Without ST-Segment Elevation

Start: Jul 2004800 patients

Phase 3Completed

NCT00202020 OtsukaCilostazol 200mg/day Oral

Efficacy and Safety Study of Cilostazol to Prevent Reoccurrence of Stroke

Start: May 2004Est. completion: Jan 2006720 patients

Phase 3Completed

NCT00050817 Sanoficlopidogrel

Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management and Avoidance (CHARISMA)

Start: Oct 2002Est. completion: Aug 200515,603 patients

Phase 3Completed

NCT00766545 Otsukacilostazol

Cilostazol Stroke Prevention Study : A Placebo-controlled Double-blind Trial for Secondary Prevention of Cerebral Infarction.

Start: Apr 1992Est. completion: Mar 19971,095 patients

Phase 3Completed

NCT00684515 MSDVorapaxar 2.5 mg

Trial to Assess the Safety of Vorapaxar in Japanese Subjects With Cerebral Infarction (P05005; MK-5348-017)

Start: Sep 2006Est. completion: Nov 200790 patients

Phase 2Completed

NCT00300339 Sanoficlopidogrel

Mixed Antagonist of Serotonin for Claudication Optimal Therapy

Start: Feb 2006Est. completion: Dec 2007599 patients

Phase 2Completed

NCT05817097 Dong-A STDipeptidyl peptidase-4 inhibitor

Effect of Dipeptidyl-4 Inhibitors in Reducing Stroke Severity, From HIRA Database

Start: Aug 2023Est. completion: Dec 202422,119 patients

N/AUnknown

NCT04973774 UNION therapeuticsA Multi-center Prospective Study of Branch Atheromatous Disease in China

A Multi-center Prospective Study of Branch Atheromatous Disease in China

Start: Jun 2021Est. completion: Jun 2025600 patients

N/AUnknown

NCT01400035 Gedeon RichterChinese Assessment for Vinpocetine In Neurology

Chinese Assessment for Vinpocetine In Neurology

Start: May 2010Est. completion: May 2013610 patients

N/ACompleted

NCT00216749 OtsukaEfficacy and Safety of Cilostazol for the Indication of CSPS

Efficacy and Safety of Cilostazol for the Indication of CSPS

Start: Dec 2003Est. completion: Oct 2007650 patients

N/ACompleted

Phase Legend

Preclinical— Lab & animal studies

Phase 1— Safety & dosing

Phase 2— Efficacy testing

Phase 3— Large-scale trials

On Market— Approved & available

Key Insights

2 late-stage (Phase 3) programs, potential near-term approvals

1 actively recruiting trials targeting 53,125 patients

10 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.